| New insights into the role of TREM2 in Alzheimer’s disease M Gratuze, CEG Leyns, DM Holtzman Molecular neurodegeneration 13 (1), 66, 2018 | 480 | 2018 |
| TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy CEG Leyns, JD Ulrich, MB Finn, FR Stewart, LJ Koscal, ... Proceedings of the National Academy of Sciences 114 (43), 11524-11529, 2017 | 429 | 2017 |
| Glial contributions to neurodegeneration in tauopathies CEG Leyns, DM Holtzman Molecular neurodegeneration 12, 1-16, 2017 | 394 | 2017 |
| TREM2 function impedes tau seeding in neuritic plaques CEG Leyns, M Gratuze, S Narasimhan, N Jain, LJ Koscal, H Jiang, ... Nature neuroscience 22 (8), 1217-1222, 2019 | 261 | 2019 |
| Impact of TREM2R47H variant on tau pathology–induced gliosis and neurodegeneration M Gratuze, CEG Leyns, AD Sauerbeck, MK St-Pierre, M Xiong, N Kim, ... The Journal of clinical investigation 130 (9), 4954-4968, 2020 | 187 | 2020 |
| Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation F Liao, A Li, M Xiong, N Bien-Ly, H Jiang, Y Zhang, MB Finn, R Hoyle, ... The Journal of clinical investigation 128 (5), 2144-2155, 2018 | 161 | 2018 |
| Intercellular spread of protein aggregates in neurodegenerative disease AA Davis, CEG Leyns, DM Holtzman Annual review of cell and developmental biology 34 (1), 545-568, 2018 | 123 | 2018 |
| AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy C Ising, G Gallardo, CEG Leyns, CH Wong, H Jiang, F Stewart, LJ Koscal, ... Journal of Experimental Medicine 214 (5), 1227-1238, 2017 | 60 | 2017 |
| Targeting tauopathy with engineered tau-degrading intrabodies G Gallardo, CH Wong, SM Ricardez, CN Mann, KH Lin, CEG Leyns, ... Molecular neurodegeneration 14, 1-12, 2019 | 54 | 2019 |
| The current state-of-the art of LRRK2-based biomarker assay development in Parkinson’s disease HJ Rideout, MC Chartier-Harlin, MJ Fell, WD Hirst, S Huntwork-Rodriguez, ... Frontiers in Neuroscience 14, 865, 2020 | 43 | 2020 |
| Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson’s disease CEG Leyns, A Prigent, B Beezhold, L Yao, NG Hatcher, P Tao, J Kang, ... npj Parkinson's Disease 9 (1), 74, 2023 | 16 | 2023 |
| Cord blood erythropoietin and hepcidin reflect lower newborn iron stores due to maternal obesity during pregnancy C Korlesky, PJ Kling, DQD Pham, AA Ovasapyan, CEG Leyns, MB Weber, ... American journal of perinatology 36 (05), 511-516, 2019 | 15 | 2019 |
| Discovery of MK-1468: a potent, kinome-selective, brain-penetrant amidoisoquinoline LRRK2 inhibitor for the potential treatment of Parkinson’s disease SD Kattar, A Gulati, KA Margrey, MH Keylor, M Ardolino, X Yan, ... Journal of Medicinal Chemistry 66 (21), 14912-14927, 2023 | 5 | 2023 |
| Correction: AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy C Ising, G Gallardo, CEG Leyns, CH Wong, H Jiang, F Stewart, LJ Koscal, ... The Journal of Experimental Medicine 214 (7), 2163, 2017 | 5 | 2017 |
| LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression N Lubben, JK Brynildsen, CM Webb, HL Li, CEG Leyns, L Changolkar, ... Translational Neurodegeneration 13 (1), 13, 2024 | 4 | 2024 |
| Microglial roles in Alzheimer's disease: An agent‐based model to elucidate microglial spatiotemporal response to beta‐amyloid C Weathered, S Bardehle, C Yoon, N Kumar, CEG Leyns, ME Kennedy, ... CPT: Pharmacometrics & Systems Pharmacology 13 (3), 449-463, 2024 | 1 | 2024 |
| LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread N Lubben, JK Brynildsen, CM Webb, HL Li, CEG Leyns, L Changolkar, ... bioRxiv, 2023.10. 06.561190, 2023 | | 2023 |
| QSP MODEL OF NEUROINFLAMMATION: EFFECT OF TREM2 STIMULATION ON MICROGLIAL ACTIVATION AND FUNCTION IN THE CONTEXT OF ALZHEIMER'S DISEASE. V Chelliah, U Sharma, D Chung, H Geerts, P van der Graaf, C Leyns, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S72-S73, 2022 | | 2022 |
| Anti-tau constructs D Holtzman, H Jiang, G Gallardo, C Ising, C Leyns US Patent App. 17/077,942, 2021 | | 2021 |
| Anti-tau constructs D Holtzman, H Jiang, G Gallardo, C Ising, C Leyns US Patent App. 16/817,339, 2020 | | 2020 |